Multiple myeloma (MM) is a blood-related malignancy resulting from the abnormal accumulation of plasma cells. This article discusses the most recent advances in B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory MM.
Non-small cell lung cancer (NSCLC) is characterized by heterogeneity and encompasses various histological subtypes. Exon 20 insertion (ex20ins) mutations of the EGFR gene have been identified as oncogenic drivers in NSCLC. This article discusses approved therapies for the treatment of NSCLC with EGFR ex20ins mutations.
Graft-vs-host disease is a severe complication of allogeneic hematopoietic cell transplantation. There is no standard of care for steroid-refractory cGVHD, and effective treatment options are limited. This article reviews the current understanding and management of this challenging disease, and highlights newer FDA-approved treatment options.
